Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities
暂无分享,去创建一个
M. Hirsch | M. Moonis | M. Osburne | A. Profy | P. Pallai | M S Osburne | S. Rusconi | M S Hirsch | A T Profy | P V Pallai | S Rusconi | D P Merrill | M Moonis | K J Willis | D. Merrill | E A Neidhardt | S K Singh | J C Jenson | K. Willis | J. Jenson | S. Singh | E. Neidhardt | Mona Moonis | M. Hirsch | Stefano Rusconi | Peter V. Pallai | Edith A. Neidhardt | Shyam K. Singh | Kevin J. Willis | Marcia S. Osburne | James C. Jenson | Martin S. Hirsch
[1] D. Markovitz,et al. The role of mononuclear phagocytes in HTLV-III/LAV infection. , 1986, Science.
[2] D. Richman,et al. Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds , 1994, Antimicrobial Agents and Chemotherapy.
[3] T. Chou,et al. Synergism and antagonism in chemotherapy , 1991 .
[4] M. Hirsch,et al. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. , 1991, The Journal of infectious diseases.
[5] R. Chaisson,et al. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection , 1991, Antimicrobial Agents and Chemotherapy.
[6] R. Gallo,et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. , 1984, Science.
[7] M. Baba,et al. Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIV-1 and HIV-2. , 1991, Journal of medicinal chemistry.
[8] E. De Clercq,et al. Sulfonic acid polymers as a new class of human immunodeficiency virus inhibitors. , 1992, Antiviral research.
[9] Roy E. Byington,et al. Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. , 1991, Disease markers.
[10] D. Ho,et al. Biological cloning of functionally diverse quasispecies of HIV-1. , 1993, AIDS research and human retroviruses.
[11] L. Callahan,et al. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions , 1991, Journal of virology.
[12] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[13] E. De Clercq,et al. Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight. , 1991, Journal of medicinal chemistry.
[14] L. D. Ward,et al. Measurement of ligand binding to proteins by fluorescence spectroscopy. , 1985, Methods in enzymology.
[15] Luc Montagnier,et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV , 1984, Nature.
[16] E. De Clercq,et al. Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds. , 1991, Journal of medicinal chemistry.
[17] S. Lederman,et al. Sulfated polyester interactions with the CD4 molecule and with the third variable loop domain (v3) of gp120 are chemically distinct. , 1992, AIDS research and human retroviruses.
[18] M. Greaves,et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.
[19] E. Reinherz,et al. A soluble multimeric recombinant CD2 protein identifies CD48 as a low affinity ligand for human CD2: divergence of CD2 ligands during the evolution of humans and mice , 1993, The Journal of experimental medicine.
[20] T. A. Hagan,et al. Detection , Isolation , and Continuous Production of Cytopathic Retroviruses ( HTLV-III ) from Patients with AIDS and Pre-AIDS , 2022 .